Douglas E. Brough
Corporate Officer/Principal bij PRECIGEN, INC.
Profiel
Douglas E.
Brough is currently the Senior Vice President & Head-Research at Precigen, Inc. Previously, he worked as the Chief Scientific Officer at GenVec, Inc. from 2013 to 2017.
Dr. Brough holds a doctorate degree from Rutgers State University of New Jersey and Robert Wood Johnson Medical School.
He also has a graduate degree from Idaho State University and an undergraduate degree from Purdue University.
Actieve functies van Douglas E. Brough
| Bedrijven | Functie | Begin |
|---|---|---|
| PRECIGEN, INC. | Corporate Officer/Principal | - |
Eerdere bekende functies van Douglas E. Brough
| Bedrijven | Functie | Einde |
|---|---|---|
| GENVEC INC | Chief Tech/Sci/R&D Officer | 16-06-2017 |
Opleiding van Douglas E. Brough
| Rutgers State University of New Jersey | Doctorate Degree |
| Idaho State University | Graduate Degree |
| Purdue University | Undergraduate Degree |
| Robert Wood Johnson Medical School | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PRECIGEN, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
GenVec, Inc.
 GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |
